AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01907529 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel, epirubicin and cyclophosphamide
Description: docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, cyclophosphamide 500mg/m2, IV (in the vein) on day 1 of each 21 day cycle; totally 4 cycles
Study NCT01907529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel, epirubicin and cyclophosphamide plus endostar
Description: docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, cyclophosphamide 500mg/m2, IV (in the vein) on day 1 of each 21 day cycle; endostar 7.5mg/m2, IV (in the vein) from day 1 to day 14, totally 4 cycles
Study NCT04076124 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active rTMS-DLPFC
Description: Participants in the rTMS active stimulation group will receive 4-week 10 Hz 120% of RMT to left DLPFC. Left side DLPFC will be targeted by MRI-neuronavigation system. Stimulation will be delivered to the L-DLPFC using a Magstim stimulator.
Study NCT04076124 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active iTBS-DLPFC
Description: Participants in the intermittent TBS(iTBS) active stimulation group will receive 4-week three-pulse 50-Hz bursts administered every 200 milliseconds (at 5 Hz) at an intensity of 80% active motor threshold (MT) to left DLPFC. Left side DLPFC will be targeted by MRI-neuronavigation system. Stimulation will be delivered to the L-DLPFC using a Magstim stimulator.
Study NCT04076124 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TBS-DLPFC or Sham rTMS-DLPFC
Description: Half of the patients in the sham group received 4-week the same iTBS parameter stimulation (sham-iTBS), and the other half received the same rTMS parameter stimulation using a sham coil (sham-rTMS), which also improved the blinding process.
Study NCT04137172 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic (IPOM) hernioplasty without repair
Description: Under general anesthesia, supine position, lateral visiport 12mm was inserted at the left anterior axillary line . Other two 5mm ports were inserted under vision. A 30-degree optics were used. Adhesiolysis was done . The contents of hernia were reduced . The borders of the defect were illuminated and outlined. The abdominal wall was marked from outside for measurement of defect size and for corners fixation of mesh with 5cm away from defect edge. Defect with axis from 9 to 12 cm is considered big defect.~Group I:~Proline (1) sutures were applied at the corners of the mesh introduced into the peritoneal cavity. Endoclose passed at the marked site from abdominal wall, sutures hanged and tied subcutaneously, completion of mesh fixation using secure strap .
Study NCT01668927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitor
Study NCT04137172 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: aparoscopic IIPOM hernioplasty with intracorporeal repair using proline 0 versus stratifix PDS
Description: Group II:~Using PDS 0, a stratifix suture (STRATAFIX™ Symmetric PDS™ Plus Knotless Tissue Control Device) versus proline 1 , used to repair and plicate the defect then mesh fixation
Study NCT04137172 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic IPOM hernioplasty with transfacial closure using PDS LOOP 0
Description: The PDS loop sutures were prepared by cutting the needles, keeping two detached ends and one blind end. A small curved supraumbilical incision was done. The endoclose passed through upper border of incision penetrating the abdominal wall above the defect, hanging the blind end of the PDS Loop to outside. It passed through the lower border of the wound crossing the defect. It hanged one detached end of the PDS Loop suture to outside, passed again through lower border of incision to catch the other detached end. The two ends were hanged not tied to avoid incision closure. The process is repeated by passing 1-2 cm lateral or medial to the previous sutures, then blind ends were divided. Lastly, all sutures are tied. Mesh was fixed as before.
Study NCT01668927 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proton Pump Inhibitor
Study NCT01240993 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mothers and Toddlers Program
Description: This intervention is a short-term attachment-based parenting therapy for substance using mothers of young children that emphasizes the development of the capacity for mentalizing.
Study NCT01240993 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent Education
Description: PE was developed to represent parent education and support that is typically available to mothers with substance use problems who are at high risk for neglecting their young children. Mothers enrolled in PEP will meet weekly for one hour with a PE counselor who will provide assistance in solving problems related to family basic needs and a choice of pamphlets on age-related parenting topics.
Study NCT00300872 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Description: Continuous positive airway pressure (CPAP) - Horizon LT 8001 Continuous positive airway pressure (CPAP) device.
Study NCT00300872 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Continuous positive airway pressure (CPAP)
Description: Sham Continuous positive airway pressure (CPAP) - Continuous positive airway pressure (CPAP) units set to the lowest pressure (4 cm of water pressure) and 6 extra 4mm holes will be inserted in the collar of the main tubing at the end of the mask to allow air escape and to prevent carbon dioxide rebreathing.
Study NCT03832868 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-visit timing of receipt of the ICDs implantation decision aid
Description: The intervention is the timing of receipt of the decision aid. The decision aid is designed to facilitate informing patients and helping to reach a decision.The implantable cardioverter-defibrillators (ICDs) implantation decision aid presents treatment options, risks, and benefits in lay terms.It is currently utilized in all of the Emory cardiac electrophysiology clinics as part of usual clinical care.
Study NCT03832868 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Post-visit timing of receipt of the ICDs implantation decision aid
Description: The intervention is the timing of receipt of the decision aid. The decision aid is designed to facilitate informing patients and helping to reach a decision.The implantable cardioverter-defibrillators (ICDs) implantation decision aid presents treatment options, risks, and benefits in lay terms.It is currently utilized in all of the Emory cardiac electrophysiology clinics as part of usual clinical care.
Study NCT00416767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Study NCT00416767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study NCT00416767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Study NCT02412644 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: apremilast
Study NCT02412644 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: apremilast
Study NCT01310595 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual mobilization on cervical spine
Description: Manual mobilization provided on selected cervical spine in patients with chronic mechanical neck apin
Study NCT01310595 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infra-red therapy with self exercise pamphlet
Description: Infra-red radiation therapy on cervical spine with self exercise pamphlet given to patients with chronic mechanical neck pain.
Study NCT01759784 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intraventricular injection
Description: intraventricular injection of mesenchymal stem cell by stereo taxi in patients with ALS
Study NCT03465735 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Vascular Boot
Description: The Vascular Boot is one size fits all, insulated fleece padding, and cell foam to enhance and maintain lower limb warmth while maintaining no pressure points on the lower extremity.
Study NCT03465735 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Standard of Care
Description: Anticoagulant therapy will be decided by physician and patient.
Study NCT03114241 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention
Description: Patients allocated to the intervention group receive a pedometer. They are encouraged to be more active by using the pedometer to measure the number of steps walked daily. An increase in step count of 15% compared to baseline will be set as the minimal goal for each patient. Monthly telephone calls are indicated to encourage compliance with the protocol and motivate patients to enhance their level of activity. The coached program ends after three months but patients keep their pedometer and are encouraged to sustain an increased level of daily physical activity for additional 9 months (end of study).
Study NCT04196036 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Day of vitrification
Description: Supernumerary embryos after fresh transfer on Day 3 after oocyte aspiration are either vitrified on Day 3 or are kept in culture until Day 5 and vitrified on Day 5
Study NCT00459407 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: biopsy
Description: Undergo biopsy
Study NCT00459407 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mass spectrometry
Description: Correlative studies
Study NCT02077049 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: serious games
Description: Execution of computer-based games that stimulate patient's mobility. The game is displayed on a Television (TV) screen and the patient's movements are detected by the sensors of the Kinect® camera, requiring therefore no game console.~The Fit Bit®, a mobility tracker device, is attached at the patient's belt the whole day and measure all the trips performed and stairs climbed.~This serious games program is instructed individually by experienced physiotherapists.
Study NCT02077049 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional self-training
Description: Participants perform conventional physical exercises that train their balance capabilities. There are instructed by experienced physiotherapists and are adapted to each patient's physical abilities. Detailed handouts are distributed to each participants.
Study NCT00780000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alvespimycin
Description: Solution, IV, Alvespimycin 80 mg/m2, Weekly one hour infusion Days 1, 8, and 15, every 4 weeks thereafter until disease progression or DLT
Study NCT02734992 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: ACT+ MTAU
Description: Participants will be randomly assigned to one of the two groups: ACT-based intervention, plus their usual health care or Medical Treatment as Usual only (MTAU). The MTAU group will follow their usual medical treatment (prescribed headache medication). Treatment sessions will be conducted weekly by two co-therapists in groups of approximately 8-10 participants for 1 ½ hour. The control group will receive the ACT intervention following the completion of the 3-months follow-up assessment of the treatment group. Participants in both groups will complete primary and secondary outcome scales, as well as ACT process effects scales at pre, post and 3-months follow-up. The treatment group only will be also assessed at 6 and 12-months follow-up. The ACT protocol and the patients' workbook were developed for the needs of the Algea project (Vasiliou \& Karekla, 2015). Techniques will focus on key ACT processes aiming at promoting psychological flexibility for the head pain experience.
Study NCT02734992 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waitlist Control +MTAU
Description: Participants in the Waitlist control+ MTAU will not receive any active intervention. Upon completion of the 3 months follow-up assessment of the ACT+MTAU group, participants allocated in the Waitlist control+MTAU will receive the ACT intervention.
Study NCT01369693 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Buccal administration of nicotine
Description: Oral pouch, oral sachet, 0.3-1g, single dose. One pouch administered between upper lip and gum over 30 minutes
Study NCT01527604 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Avenanthramide-enriched oats
Description: avenanthramide-enriched oats, delivered as muffins at a dose of 2 muffins per day for 56 days.
Study NCT01527604 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Refined flour absent avenanthramides
Description: refined flour absent avenanthramides, delivered as muffins at a dose of 2 muffins per day for 56 days.
Study NCT03020524 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous CD4 T-Cells
Description: all participants will receive a single infusion of C34-CXCR4-modified CD4+ T-cells at one of 3 dose levels. The first 3 subjects will receive dose level 1 of 0.8-1x109 transduced CD4+T-cells. Provided no dose limiting toxicity (DLT) is seen at the first dose level, the next 3 subjects will receive infusion at the 2nd dose level of 2.4-3x109 transduced CD4+ T-cells. If no DLT occurs at that dose, the final 3 subjects will receive the 3rd dose level of 0.8-1x1010 transduced CD4+ T-cells. In the event of a DLT (grade 3 or higher unexpected, related AE) recruitment will be paused pending DSMB decision
Study NCT03020524 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Autologous CD4 T-Cells
Description: all participants will receive a single infusion of C34-CXCR4-modified CD4+ T-cells at one of 3 dose levels. The first 3 subjects will receive dose level 1 of 0.8-1x109 transduced CD4+T-cells. Provided no dose limiting toxicity (DLT) is seen at the first dose level, the next 3 subjects will receive infusion at the 2nd dose level of 2.4-3x109 transduced CD4+ T-cells. If no DLT occurs at that dose, the final 3 subjects will receive the 3rd dose level of 0.8-1x1010 transduced CD4+ T-cells. In the event of a DLT (grade 3 or higher unexpected, related AE) recruitment will be paused pending DSMB decision
Study NCT04051567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 100mg
Description: In LDA group, patients were asked for taking 100mg aspirin per night;
Study NCT04064684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Enrolled patients will be treated with Pulmicort Respules® (Budesonide inhalation suspension), at a dose of 0.5 mg, nebulized twice daily through the mechanical ventilator. The medication will be administered to the patient by the respiratory therapist with the single-patient-use medication nebulizer attached to the mechanical ventilator circuit. The maximum length of treatment will be 10 days.
Study NCT04064684 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Enrolled patients will be treated with normal saline.The medication will be administered to the patient by the respiratory therapist with the single-patient-use medication nebulizer attached to the mechanical ventilator circuit. The maximum length of treatment will be 10 days.
Study NCT04064684 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nebulizer
Description: The medication will be administered to the patient by the respiratory therapist with the single-patient-use medication nebulizer attached to the mechanical ventilator circuit.
Study NCT04064684 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Nebulizer
Description: The medication will be administered to the patient by the respiratory therapist with the single-patient-use medication nebulizer attached to the mechanical ventilator circuit.
Study NCT04688567 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-driven iCBT
Description: 1) Participants who are randomized to the experimental condition are asked to make choices regarding the structure of their treatment by the time of the randomization call. The participant can choose which of the available treatment programs (targeting anxiety, worry, stress, sleep disorders or depression) they want to undergo, how many modules in the treatment program they want to complete and in what order, for how many weeks they want to complete the treatment as well as how much telephone contact and how much written contact they want to have with their therapist.
Study NCT04688567 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standardized iCBT (TAU)
Description: 2) Patients who are randomized to the control condition (standardized iCBT) undergo the usual iCBT program available for anxiety disorders for 8 weeks. The psychologist provide weekly feedback on the patient's exercises and interact with the patient via secure encrypted messages in the treatment program. A follow-up telephone call takes place at the middle of treatment and at the end of the treatment.
Study NCT04069767 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ICoreDIST
Description: The intervention consists of exercises that demand enhancement of dynamic trunk stability and functional movements, combined with the following:~1. Optimised alignment and adaptation to the base of support and often using an unstable reference point for the trunk (therapeutic ball) or the distal body parts.~2. Enhanced somatosensory integration of hands, feet and face, including reduced influence of vision to enhance somatosensory integration.~3. Proximal stability prior to selective task-oriented movement of limbs, head, eyes.~4. Inclusion of dual tasks (motor/motor and motor/cognitive) in exercises and activities such as walking indoors, out-doors and climbing stairs.~5. Specific hands-on interactions or other adaptations to optimise alignment and neuromuscular recruitment.~6. Exercises combining core activation and moderate increase in heart rate: in lying, sitting, standing and walking.
Study NCT04069767 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: According to national guidelines for stroke care, every patient in Norway will receive in-patient rehabilitation, home-based and out-patient based physiotherapy.
Study NCT03731416 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: GBR by xenograft and autogenous bone
Description: Ridge augmentation by native collagen membrane and mix of anorganic bovine bone derived mineral with particulated autogenous bone chips (ratio 1:1).
Study NCT03731416 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: GBR by xenograft and autogenous bone
Description: Ridge augmentation by native collagen membrane and mix of anorganic bovine bone derived mineral with particulated autogenous bone chips (ratio 1:1).
Study NCT03130101 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Change in their basal insulin rate
Description: Individual with type 1 diabetes on insulin pump therapy typically lower their basal insulin delivery for exercise. This study will compare 3 common strategies of basal insulin reductions for 75 minutes of aerobic exercise.
Study NCT01668927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth
Study NCT01668927 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth
Study NCT01300780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoricoxib
Description: Group 2 - experimental Etoricoxib will receive two doses of selective anti-inflammatory to enzyme cyclooxygenase 2 (COX-2) (Etoricoxib 60 mg) given once every 24 hours;
Study NCT00459407 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: mass spectrometry
Description: Correlative studies
Study NCT00459407 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high performance liquid chromatography
Description: Correlative studies
Study NCT00459407 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: high performance liquid chromatography
Description: Correlative studies
Study NCT00433745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WT1 Peptide Vaccine
Description: WT1 vaccination (9 doses of WT-1:126-134 peptide (in Montanide adjuvant) administered concomitantly with GM-CSF (Sargramostim)
Study NCT01300780 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Group 1 - Control Group will receive two doses of placebo tablet administered a every 8 hours,
Study NCT00128219 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBS III-TT
Description: 50 mcg GBS Type III capsular polysaccharide conjugated to 32 mcg of tetanus toxoid. A single dose of vaccine administered by intramuscular (IM) injection in the upper arm. All subjects will receive a volume of 0.5 ml.
Study NCT00128219 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tetanus and diptheria toxoids vaccine
Description: Td vaccine is a sterile solution of alum-precipitated toxoids in isotonic sodium chloride solution. A single dose of vaccine will be administered by intramuscular (IM) injection in the upper arm. All subjects will receive a volume of 0.5 ml. Each 0.5 ml dose is formulated to contain 5 Lf (flocculation units) of tetanus toxoid and 2 Lf of diphtheria toxoid.
Study NCT00674908 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shan 5
Description: Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib tetanus toxoid conjugate pentavalent liquid combination vaccine
Study NCT03911271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.1% atropine and 0.01% atropine
Description: 0.1% atropine loading dose for 6 months followed by 0.01% atropine for 18 months